Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment

Christian Rolfo*, Judith de Vos-Geelen, Nicolas Isambert, L. Rhoda Molife, Jan H. M. Schellens, Jacques De Greve, Luc Dirix, Peter Grundtvig-Sorensen, Guy Jerusalem, Karin Leunen, Morten Mau-Sorensen, Ruth Plummer, Maria Learoyd, Wendy Bannister, Anitra Fielding, Alain Ravaud

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1165-1174
Number of pages10
JournalClinical Pharmacokinetics
Volume58
Issue number9
DOIs
Publication statusPublished - Sep 2019

Keywords

  • INHIBITOR
  • CANCER

Cite this

Rolfo, C., de Vos-Geelen, J., Isambert, N., Molife, L. R., Schellens, J. H. M., De Greve, J., Dirix, L., Grundtvig-Sorensen, P., Jerusalem, G., Leunen, K., Mau-Sorensen, M., Plummer, R., Learoyd, M., Bannister, W., Fielding, A., & Ravaud, A. (2019). Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment. Clinical Pharmacokinetics, 58(9), 1165-1174. https://doi.org/10.1007/s40262-019-00754-4